Clinical Oncology
IF
4.13
Papers
6,626
Papers 6,504
1 page of 651 pages (6,504 results)
Newest
#1P.L. Yip (Tuen Mun Hospital)
#2K.C.J. Mok (Tuen Mun Hospital)
Last. S.F. Lee (HKU: University of Hong Kong)
view all 9 authors...
Abstract null null Aims null Hearing loss is a common debilitating complication in nasopharyngeal carcinoma (NPC) survivors. The aim of the present study was to investigate the impact of inner ear/cochlear radiation dose and cisplatin use on early and late sensorineural hearing loss (SNHL) in NPC patients treated with radiotherapy alone, concurrent chemoradiation (cCRT) and induction chemotherapy followed by cCRT (iCRT) in the intensity-modulated radiotherapy era. null null null Materials and me...
Source
#1Gerard Walls (Belfast Health and Social Care Trust)H-Index: 7
#2S.O.S. Osman (Belfast Health and Social Care Trust)
Last. Suneil Jain (Belfast Health and Social Care Trust)H-Index: 29
view all 11 authors...
Lung cancer's radiomic phenotype may potentially inform clinical decision-making with respect to radical radiotherapy. At present there are no validated biomarkers available for the individualisation of radical radiotherapy in lung cancer and the mortality rate of this disease remains the highest of all other solid tumours. MEDLINE was searched using the terms 'radiomics' and 'lung cancer' according to the Preferred Reporting Items for Systematic Reviews and Met-Analyses (PRISMA) guidance. Radio...
Source
#1J. Van Heerden (SU: Stellenbosch University)H-Index: 10
#2Tonya M. Esterhuizen (UCT: University of Cape Town)H-Index: 25
view all 12 authors...
Abstract null null Aims null Image-defined risk factors (IDRFs) in neuroblastoma predict surgical complications and management outcomes. As there is a lack of data regarding the association of IDRFs with clinical and pathological factors, this study evaluated the prognostic value of IDRFs to predict neuroblastoma survival outcomes. null null null Materials and methods null This was a retrospective study including 345 patients and reviewed diagnostic imaging for 20 IDRFs, pleural effusions and as...
Source
#1Umesh Mahantshetty (HBNI: Homi Bhabha National Institute)H-Index: 12
#2P. Naga (HBNI: Homi Bhabha National Institute)
Last. Shyamkishore Shrivastava (HBNI: Homi Bhabha National Institute)H-Index: 19
view all 10 authors...
Abstract null null Aims null Uterocervical motions and organ filling during cervical cancer conformal radiotherapy is complex. This prospective, observational study investigated set-up margins (clinical target vo, ume [CTV] to planning target volume [PTV]) for pelvic nodal CTV and internal margin (CTV to internal target volume [ITV]) expansions for uterocervical movements during cervical cancer radiotherapy. null null null Materials and methods null During cervical cancer radiotherapy, a daily k...
Source
#1Meixia Zhang (SCU: Sichuan University)H-Index: 6
#2X. Liu (SCU: Sichuan University)
Last. Qianrui Li (SCU: Sichuan University)H-Index: 10
view all 7 authors...
Abstract null null Aims null The EMPOWER-Lung 1 trial showed that cemiplimab significantly prolongs the duration of progression-free survival and overall survival in advanced non-small cell lung cancer (NSCLC) patients with at least 50% programmed cell death receptor ligand-1 (PD-L1) positivity, yet the financial burden may limit its use. The aim of the present study was to evaluate the cost-effectiveness of cemiplimab versus chemotherapy in a US setting. null null null Materials and methods nul...
Source
#1A. Nathan (RCS: Royal College of Surgeons of England)
#2A Ng (UCL: University College London)
Last. H. Payne (UCL: University College London)H-Index: 6
view all 13 authors...
Abstract null null Aims null Ablative therapy, such as focal therapy, cryotherapy or electroporation, aims to treat clinically significant prostate cancer with reduced treatment-related toxicity. Up to a third of patients may require further local salvage treatment after ablative therapy failure. Limited descriptive, but no comparative, evidence exists between different salvage treatment outcomes. The aim of this study was to compare oncological and functional outcomes after salvage robot-assist...
Source
#1J.S. Lim (University of Southampton)
#2H.L. Goh (Guy's and St Thomas' NHS Foundation Trust)
Last. I.S. Boon
view all 5 authors...
Source
#1P. Khurud (HBNI: Homi Bhabha National Institute)
#2Rahul Krishnatry (HBNI: Homi Bhabha National Institute)H-Index: 14
Last. Vedang Murthy (HBNI: Homi Bhabha National Institute)H-Index: 7
view all 12 authors...
AIMS Due to the lack of high-quality evidence and consensus on adjuvant treatment for locoregionally advanced penile cancer, we reviewed the outcomes of pN3 patients to determine the suitable adjuvant treatment options. PATIENTS AND METHODS All consecutive pN3 penile cancer patients treated at our institution between January 2010 and December 2018 were reviewed to assess the impact of demographical, pathological and treatment factors on disease-free survival (DFS) and overall survival. The DFS a...
Source
#1Soumyajit Roy (Rush University Medical Center)
#2Scott C. Morgan (University of Ottawa)H-Index: 17
Last. Shawn Malone (University of Ottawa)H-Index: 29
view all 8 authors...
Abstract null null Aims null Although health-related quality of life (HR-QoL) outcomes are pivotal in oncology, the prognostic significance of patient-reported HR-QoL metrics is largely undefined in localised prostate cancer. We report the association of baseline HR-QoL metrics with overall survival and toxicity in localised prostate cancer. null null null Materials and methods null This was a secondary analysis of a phase III randomised controlled study conducted in a single-payer health system...
Source
#1Helen McNair (NHS: National Health Service)H-Index: 29
#2Kevin Franks (Leeds Teaching Hospitals NHS Trust)H-Index: 21
Last. M. van Herk (University of Manchester)H-Index: 31
view all 3 authors...
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.